ClinicalTrials.gg
CompletedNCT01241591Updated Dec 26, 2018Results posted

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of CP 690,550 5 mg and CP 690,550 10 mg in Psoriasis, sponsored by Pfizer. Completed at 122 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-26.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,101
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.

Enrollment
2nd of 19
1,101 · median 135
Started
2010
with 2 others
Phase 3
9 of 19
1 open now
Registered
5th of 19
by date
Lead sponsor
14 of 19
Pfizer

Among the 19 studies testing tofacitinib in Psoriasis, this one is the 2nd largest by enrollment, is one of 3 that started in 2010, is one of 9 in phase 3, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tofacitinib in Psoriasis, or all of them as a file.
02

Study summary

To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.

03

Conditions studied

  • Psoriasis

Keywords

  • CP-690,550
  • Etanercept
  • Moderate
  • Severe
  • Chronic
  • Plaque
  • Psoriasis
  • Efficacy
  • Safety
  • Tofacitinib
  • Xeljanz
  • OPT Compare
  • OPT
  • head-to-head
  • non-inferiority
  • Psoriasis vulgaris
  • short-term
  • Itch
  • Pruritus
  • Plaque psoriasis
  • DLQI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris);
  • Have plaque-type psoriasis covering at least 10% of total body surface area
  • Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis

Exclusion criteria

Exclusion Criteria:

  • Non-plaque or drug induced forms of psoriasis
  • Cannot discontinue current systemic and/or topical therapies for the treatment of psoriasis
  • Cannot discontinue phototherapy
  • Any uncontrolled significant medical condition
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,101 participants (actual)

Study arms

  • Experimental
    CP 690,550 5 mg BID+Placebo BIW

    Drug: CP 690,550 5 mg

  • Experimental
    CP 690,550 10 mg BID+Placebo BIW

    Drug: CP 690,550 10 mg

  • Active comparator
    Placebo BID+Etanercept 50 mg BIW

    Biological: Etanercept 50 mg

  • Placebo comparator
    Placebo BID+Placebo BIW

    Other: Placebo

Interventions

  • CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

  • CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

  • Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks

  • OtherPlacebo

    Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

    Time frame: Week 12

  2. Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to baseline/Day 1.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants With a PGA Response of "Clear" or "Almost Clear" During the 12-Week Double-Blind Treatment

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response is defined as 0 (clear) or 1 (almost clear).

    Time frame: Weeks 2, 4, and 8

  2. Percentage of Participants in Each PGA Category During the 12-Week Double-Blind Treatment

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).

    Time frame: Baseline and Weeks 2, 4, 8, and 12

  3. Percentage of Participants With a PASI75 Response During the 12-Week Double-Blind Treatment

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to baseline/Day 1.

    Time frame: Weeks 2, 4, and 8

  4. Mean PASI Score During the 12-Week Double-Blind Treatment

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

    Time frame: Baseline and Weeks 2, 4, 8, and 12

  5. Mean Change From Baseline in PASI Score During the 12-Week Double-Blind Treatment

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

    Time frame: Weeks 2, 4, 8, and 12

  6. Mean PASI Component Scores by Body Region During the 12-Week Double Blind Treatment

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

    Time frame: Baseline and Weeks 2, 4, 8, and 12

  7. Mean Change From Baseline in PASI Component Scores by Body Region During the 12-Week Double Blind Treatment

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

    Time frame: Weeks 2, 4, 8, and 12

  8. Mean Percentage of Total Psoriatic BSA During the 12-Week Double-Blind Treatment

    Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The % surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

    Time frame: Baseline and Weeks 2, 4, 8, and 12

  9. Mean Percent Change From Baseline in Total Psoriatic BSA During the 12-Week Double-Blind Treatment

    Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant(fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

    Time frame: Weeks 2, 4, 8, and 12

  10. Percentage of Participants Who Achieved a 50% Reduction in PASI Relative to Baseline (PASI50) During the 12-Week Double-Blind Treatment

    PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.

    Time frame: Weeks 2, 4, 8, and 12

  11. Median Time to PASI50 Response During the 12-Week Double-Blind Treatment

    Time frame: Baseline up to Week 12

  12. Percentage of Participants Who Achieved a 90% Reduction in PASI Relative to Baseline (PASI90) During the 12-Week Double-Blind Treatment

    PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.

    Time frame: Weeks 2, 4, 8, and 12

  13. Median Time to Achieve PASI75 Response During the 12-Week Double-Blind Treatment

    Time frame: Baseline up to Week 12

  14. Percentage of Participants With a PASI Score Greater Than or Equal to (≥)125% of the Baseline PASI Score During the 12-Week Double-Blind Treatment

    Time frame: Weeks 2, 4, 8, and 12

  15. Mean Itch Severity Item (ISI) Score During the 12-Week Double-Blind Treatment

    ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  16. Mean Change From Baseline in ISI Score During the 12-Week Double-Blind Treatment

    ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 2, 4, 8, and 12

  17. Percentage of Participants Achieving an ISI Score of 0 During the 12-Week Double-Blind Treatment

    ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 2, 4, 8, and 12

  18. Mean Dermatology Life Quality Index (DLQI) Score During the 12-Week Double-Blind Treatment

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline and Weeks 4 and 12

  19. Mean Change From Baseline in DLQI Score During the 12-Week Double-Blind Treatment

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4 and 12

  20. Mean DLQI Subscale Scores During the 12-Week Double-Blind Treatment

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).

    Time frame: Baseline and Weeks 4 and 12

  21. Mean Change From Baseline in DLQI Subscale Scores During the 12-Week Double-Blind Treatment

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4 and 12

  22. Percentage of Participants Achieving DLQI Response ≥5 During the 12-Week Double-Blind Treatment

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Weeks 4 and 12

  23. Percentage of Participants Achieving DLQI Response ≤1 During the 12-Week Double-Blind Treatment

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Weeks 4 and 12

  24. Median Time to DLQI Response

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. DLQI Response was defined as a 5-point reduction in the total DLQI score.

    Time frame: Weeks 4 and 12

  25. Mean Short Form 36 (SF-36) Mental Component Summary (MCS) and Physical Component Summary (PCS) Scores at Baseline and Week 12

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Higher scores indicate a better health related quality of life.

    Time frame: Baseline and Week 12

  26. Mean SF-36 Domain Scores at Baseline and Week 12

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.

    Time frame: Baseline and Week 12

  27. Mean Change From Baseline in SF-36 MCS and PCS Scores

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Higher scores indicate a better health related quality of life.

    Time frame: Week 12

  28. Mean Change From Baseline in SF-36 Domain Scores

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.

    Time frame: Week 12

  29. Percentage of Participants in Each Patient Global Assessment of Psoriasis (PtGA) Category During the 12-Week Double-Blind Treatment

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).

    Time frame: Baseline and Weeks 2, 4, and 8

  30. Percentage of Participants With a PtGA Response During the 12-Week Double-Blind Treatment

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe). Response defined as score of 0 or 1.

    Time frame: Weeks 2, 4, 8, and 12

  31. Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Category During the 12-Week Double-Blind Treatment

    The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study medication.

    Time frame: Week 12

  32. Percentage of Participants Achieving PSSM Response of 'Very Satisfied' or 'Somewhat Satisfied' at Week 12

    The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study medication.

    Time frame: Week 12

  33. Mean European Quality of Life 5 Dimension (EQ-5D) Health State Utility Score During the 12-Week Double-Blind Treatment

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Baseline and Week 12

  34. Least Squares (LS) Mean Change From Baseline in EQ-5D Health State Utility Score During the 12-Week Double-Blind Treatment

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Week 12

  35. Mean EQ-5D Visual Analog Score (VAS) During the 12-Week Double-Blind Treatment

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline and Week 12

  36. Mean Change From Baseline in EQ-5D VAS at Week 12

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Time frame: Week 12

  37. Dimension Health State EQ-5D Score During the 12-Week Double-Blind Treatment

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").

    Time frame: Baseline and Week 12

  38. Mean Change From Baseline in EQ-5D Dimension Health State Score at Week 12

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").

    Time frame: Week 12

  39. Percentage of Participants Interacting With Healthcare Professionals During the 12-Week Double-Blind Treatment

    The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners \[GPs\], primary care physicians \[PCPs\], or family medicine physicians \[FMP\], emergency room visits, and hospitalizations), and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work.

    Time frame: Baseline (BL) and Week 12

  40. Percentage of Participants Reporting Healthcare Resource Use Events During the 12-Week Double-Blind Treatment

    Time frame: Week 12

  41. Percentage of Participants Employed or Not Employed and the Impact of Psoriasis on Work

    Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The questionnaire assesses employment status of participant (employed: yes or no) and if currently employed it asks the participant if they were absent or on sick leave from work due to psoriasis; if unemployed it asks the participant if the unemployment is due to psoriasis.

    Time frame: Baseline and Week 12

  42. Percentage of Participants Reporting Work-Impacted Events During the 12-Week Double-Blind Treatment

    Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.

    Time frame: Week 12

  43. Mean Psoriasis Quality of Life 12 (PQOL-12) Score During the 12-Week Double-Blind Treatment

    The PQOL-12 is a 12-item questionnaire; 8 of the items on the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.

    Time frame: Baseline and Week 12

  44. Mean Change From Baseline in PQOL-12 Score During the 12-Week Double-Blind Treatment

    The PQOL-12 is a 12-item questionnaire; 8 of the items on the PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.

    Time frame: Week 12

07

Results

Posted May 7, 2014
Limitations and caveats
Clinical interpretation regarding sub-phenotypes of psoriasis (e.g., scalp psoriasis) should not be made based on the reported assessments by body regions. For example, the body region of head does not reflect solely scalp psoriasis.

Participant flow

Participant flow — Overall Study
MilestoneCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Started329330335107
Completed30630631395
Not completed23242212
Withdrew: Lack of efficacy5223
Withdrew: Protocol violation5230
Withdrew: Lost to follow-up1222
Withdrew: Screen failure3210
Withdrew: Withdrawal by subject6422
Withdrew: Other0101
Withdrew: Adverse event311124

Outcome measures

PrimaryPercentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 1247.1168.1866.2714.95
Statistical analysis
  • CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) vs Placebo BID + Etanercept 50 mg BIW · Mean difference: -19.16 · 95% CI -26.55 to -11.76
  • CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) vs Placebo BID + Placebo BIW · Mean difference: 32.16 · 95% CI 23.51 to 40.81
  • CP-690,550 10 mg BID + Placebo BIW vs Placebo BID + Etanercept 50 mg BIW · Mean difference: 1.91 · 95% CI -5.22 to 9.05
  • CP-690,550 10 mg BID + Placebo BIW vs Placebo BID + Placebo BIW · Mean difference: 53.23 · 95% CI 44.81 to 61.65
PrimaryPercentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to baseline/Day 1.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 1239.5163.6458.815.61
Statistical analysis
  • CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) vs Placebo BID + Etanercept 50 mg BIW · Mean difference: -19.29 · 95% CI -26.75 to -11.83
  • CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) vs Placebo BID + Placebo BIW · Mean difference: 33.91 · 95% CI 27.06 to 40.76
  • CP-690,550 10 mg BID + Placebo BIW vs Placebo BID + Etanercept 50 mg BIW · Mean difference: 4.83 · 95% CI -2.57 to 12.23
  • CP-690,550 10 mg BID + Placebo BIW vs Placebo BID + Placebo BIW · Mean difference: 58.03 · 95% CI 51.25 to 64.81
SecondaryPercentage of Participants With a PGA Response of "Clear" or "Almost Clear" During the 12-Week Double-Blind Treatment

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response is defined as 0 (clear) or 1 (almost clear).

Time frame:
Weeks 2, 4, and 8
Reported as:
Number · percentage of participants
Percentage of Participants With a PGA Response of "Clear" or "Almost Clear" During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 2 (n=325,326,331,107)6.7710.747.851.87
Week 4 (n=320,323,328,102)21.2535.9128.353.92
Week 8 (n=314,316,322,100)40.4563.6160.8713.00
SecondaryPercentage of Participants in Each PGA Category During the 12-Week Double-Blind Treatment

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).

Time frame:
Baseline and Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants in Each PGA Category During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline, Clear (n=329,330,335,107)0.00.00.00.0
Baseline, Almost Clear (n=329,330,335,107)0.00.00.00.0
Baseline, Mild (n=329,330,335,107)1.81.21.22.8
Baseline, Moderate (n=329,330,335,107)80.283.380.982.2
Baseline, Severe (n=329,330,335,107)17.915.517.915.0
Week 2, Clear (n=325,326,331,107)0.00.00.00.0
Week 2, Almost Clear (n=325,326,331,107)6.810.77.91.9
Week 2, Mild (n=325,326,331,107)38.547.942.625.2
Week 2, Moderate (n=325,326,331,107)48.938.345.664.5
Week 2, Severe (n=325,326,331,107)5.83.13.98.4
Week 4, Clear (n=320,323,328,102)1.92.50.60.0
Week 4, Almost Clear (n=320,323,328,102)19.433.427.73.9
Week 4, Mild (n=320,323,328,102)46.344.351.534.3
Week 4, Moderate (n=320,323,328,102)30.017.619.555.9
Week 4, Severe (n=320,323,328,102)2.52.20.65.9
Week 8, Clear (n=314,316,322,100)5.414.29.00.0
Week 8, Almost Clear (n=314,316,322,100)35.049.451.913.0
Week 8, Mild (n=314,316,322,100)41.425.030.135.0
Week 8, Moderate (n=314,316,322,100)15.910.88.149.0
Week 8, Severe (n=314,316,322,100)2.20.60.93.0
Week 12, Clear (n=314,316,322,100)11.827.021.02.1
Week 12, Almost Clear (n=313,311,309,95)37.745.350.814.7
Week 12, Mild (n=313,311,309,95)33.519.321.436.8
Week 12, Moderate (n=313,311,309,95)15.77.45.542.1
Week 12, Severe (n=313,311,309,95)1.31.01.34.2
SecondaryPercentage of Participants With a PASI75 Response During the 12-Week Double-Blind Treatment

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to baseline/Day 1.

Time frame:
Weeks 2, 4, and 8
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI75 Response During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 2 (n=326,327,331,106)1.532.750.910.00
Week 4 (n=319,323,328,102)10.3419.818.230.00
Week 8 (n=315,319,323,99)28.5752.3542.723.03
SecondaryMean PASI Score During the 12-Week Double-Blind Treatment

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

Time frame:
Baseline and Weeks 2, 4, 8, and 12
Reported as:
Mean · score on a scale
Mean PASI Score During the 12-Week Double-Blind Treatment
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline (n=329,330,335,107)23.13 ± 0.4823.29 ± 0.5322.73 ± 0.5322.78 ± 0.88
Week 2 (n=326,327,328,102)18.16 ± 0.4716.81 ± 0.5317.29 ± 0.4921.26 ± 0.95
Week 4 (n=319,323,328,102)14.46 ± 0.4612.13 ± 0.5212.73 ± 0.4420.06 ± 0.94
Week 8 (n=315,319,323,99)10.63 ± 0.447.59 ± 0.487.70 ± 0.3817.91 ± 0.99
Week 12 (n=313,311,309,95)8.80 ± 0.435.77 ± 0.455.42 ± 0.3617.39 ± 1.06
SecondaryMean Change From Baseline in PASI Score During the 12-Week Double-Blind Treatment

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Mean · scores on a scale
Mean Change From Baseline in PASI Score During the 12-Week Double-Blind Treatment
scores on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 2 (n=326,327,331,106)-5.03 ± 0.31-6.47 ± 0.31-5.48 ± 0.29-1.58 ± 0.46
Week 4 (n=319,323,328,102)-8.83 ± 0.42-11.30 ± 0.43-10.14 ± 0.39-2.58 ± 0.62
Week 8 (n=315,319,323,99)-12.62 ± 0.52-15.81 ± 0.51-15.20 ± 0.51-4.82 ± 0.81
Week 12 (n=313,311,309,95)-14.55 ± 0.60-17.54 ± 0.54-17.55 ± 0.57-5.33 ± 0.97
SecondaryMean PASI Component Scores by Body Region During the 12-Week Double Blind Treatment

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

Time frame:
Baseline and Weeks 2, 4, 8, and 12
Reported as:
Mean · score on a scale
Mean PASI Component Scores by Body Region During the 12-Week Double Blind Treatment
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Head/Neck Erythema, Baseline (n=329,329,335,107)2.28 ± 0.052.36 ± 0.052.32 ± 0.052.40 ± 0.09
Head/Neck Erythema, Week 2 (n=326,326,331,106)1.82 ± 0.051.65 ± 0.051.76 ± 0.062.27 ± 0.09
Head/Neck Erythema, Week 4 (n=320,323,328,102)1.48 ± 0.051.18 ± 0.051.23 ± 0.052.03 ± 0.09
Head/Neck Erythema, Week 8 (n=315,319,323,99)1.19 ± 0.060.78 ± 0.050.69 ± 0.051.89 ± 0.10
Head/Neck Erythema, Week 12 (n=313,311,309,95)1.04 ± 0.060.65 ± 0.050.48 ± 0.041.74 ± 0.11
Head/Neck Induration, Baseline (n=329,329,335,107)2.04 ± 0.052.08 ± 0.051.96 ± 0.062.12 ± 0.10
Head/Neck Induration, Week 2 (n=326,326,331,106)1.60 ± 0.051.44 ± 0.051.46 ± 0.061.97 ± 0.10
Head/Neck Induration, Week 4 (n=320,323,328,102)1.21 ± 0.050.94 ± 0.051.01 ± 0.051.69 ± 0.10
Head/Neck Induration, Week 8 (n=315,319,323,99)0.96 ± 0.050.59 ± 0.050.54 ± 0.051.57 ± 0.10
Head/Neck Induration, Week 12 (n=313,311,309,95)0.87 ± 0.050.49 ± 0.040.37 ± 0.041.41 ± 0.11
Head/Neck Scaling, Baseline (n=329,329,335,107)2.29 ± 0.062.38 ± 0.062.28 ± 0.062.33 ± 0.10
Head/Neck Scaling, Week 2 (n=326,326,331,106)1.75 ± 0.061.63 ± 0.061.60 ± 0.062.15 ± 0.10
Head/Neck Scaling, Week 4 (n=320,323,328,102)1.38 ± 0.061.07 ± 0.061.16 ± 0.051.80 ± 0.11
Head/Neck Scaling, Week 8 (n=315,319,323,99)1.12 ± 0.060.70 ± 0.050.65 ± 0.051.66 ± 0.11
Head/Neck Scaling, Week 12 (n=313,311,309,95)0.98 ± 0.060.60 ± 0.050.46 ± 0.051.51 ± 0.11
Upper Limbs Erythema, Baseline (n=329,329,335,107)2.87 ± 0.042.87 ± 0.042.88 ± 0.042.92 ± 0.07
Upper Limbs Erythema, Week 2 (n=326,326,331,106)2.35 ± 0.042.18 ± 0.052.27 ± 0.052.75 ± 0.07
Upper Limbs Erythema, Week 4 (n=320,323,328,102)1.92 ± 0.051.73 ± 0.051.77 ± 0.052.61 ± 0.07
Upper Limbs Erythema, Week 8 (n=315,319,323,99)1.55 ± 0.051.27 ± 0.051.25 ± 0.052.42 ± 0.08
Upper Limbs Erythema, Week 12 (n=313,311,309,95)1.45 ± 0.061.07 ± 0.050.94 ± 0.052.32 ± 0.08
Upper Limbs Induration Baseline(n=329,329,335,107)2.69 ± 0.042.76 ± 0.042.72 ± 0.042.79 ± 0.07
Upper Limbs Induration, Week 2 (n=326,326,331,106)2.17 ± 0.052.03 ± 0.052.13 ± 0.052.54 ± 0.07
Upper Limbs Induration, Week 4 (n=320,323,328,102)1.76 ± 0.051.54 ± 0.051.59 ± 0.052.36 ± 0.08
Upper Limbs Induration, Week 8 (n=315,319,323,99)1.43 ± 0.061.13 ± 0.051.18 ± 0.052.12 ± 0.09
Upper Limbs Induration, Week 12 (n=313,311,309,95)1.31 ± 0.061.01 ± 0.050.81 ± 0.052.08 ± 0.09
Upper Limbs Scaling, Baseline (n=329,329,335,107)2.66 ± 0.042.72 ± 0.042.73 ± 0.042.63 ± 0.08
Upper Limbs Scaling, Week 2 (n=326,326,331,106)2.11 ± 0.052.00 ± 0.052.03 ± 0.052.35 ± 0.09
Upper Limbs Scaling, Week 4 (n=320,323,328,102)1.71 ± 0.051.50 ± 0.051.54 ± 0.052.22 ± 0.10
Upper Limbs Scaling, Week 8 (n=315,319,323,99)1.39 ± 0.061.11 ± 0.051.07 ± 0.051.98 ± 0.09
Upper Limbs Scaling, Week 12 (n=313,311,309,95)1.30 ± 0.061.00 ± 0.050.82 ± 0.051.95 ± 0.10
Trunk Erythema, Baseline (n=329,329,335,107)2.95 ± 0.042.88 ± 0.042.91 ± 0.042.97 ± 0.06
Trunk Erythema, Week 2 (n=326,326,331,106)2.40 ± 0.052.20 ± 0.052.27 ± 0.052.75 ± 0.07
Trunk Erythema, Week 4 (n=320,323,328,102)2.03 ± 0.051.75 ± 0.051.76 ± 0.052.59 ± 0.07
Trunk Erythema, Week 8 (n=315,319,323,99)1.71 ± 0.061.23 ± 0.051.24 ± 0.052.41 ± 0.09
Trunk Erythema, Week 12 (n=313,311,309,95)1.53 ± 0.060.97 ± 0.060.89 ± 0.052.33 ± 0.10
Trunk Induration, Baseline (n=329,329,335,107)2.75 ± 0.042.70 ± 0.052.66 ± 0.052.66 ± 0.07
Trunk Induration, Week 2 (n=326,326,331,106)2.26 ± 0.052.01 ± 0.052.05 ± 0.052.40 ± 0.07
Trunk Induration, Week 4 (n=320,323,328,102)1.83 ± 0.051.50 ± 0.051.50 ± 0.052.26 ± 0.07
Trunk Induration, Week 8 (n=315,319,323,99)1.50 ± 0.060.97 ± 0.050.98 ± 0.052.06 ± 0.09
Trunk Induration, Week 12 (n=313,311,309,95)1.33 ± 0.060.80 ± 0.050.66 ± 0.052.03 ± 0.09
Trunk Scaling, Baseline (n=329,329,335,107)2.64 ± 0.042.66 ± 0.052.57 ± 0.052.61 ± 0.07
Trunk Scaling, Week 2 (n=326,326,331,106)2.12 ± 0.051.92 ± 0.061.93 ± 0.052.36 ± 0.09
Trunk Scaling, Week 4 (n=320,323,328,102)1.73 ± 0.051.39 ± 0.051.44 ± 0.052.12 ± 0.09
Trunk Scaling, Week 8 (n=315,319,323,99)1.47 ± 0.060.94 ± 0.050.90 ± 0.051.86 ± 0.08
Trunk Scaling, Week 12 (n=313,311,309,95)1.28 ± 0.060.74 ± 0.050.62 ± 0.051.91 ± 0.10
Lower Limbs Erythema, Baseline (n=329,329,335,107)3.12 ± 0.033.13 ± 0.043.14 ± 0.033.10 ± 0.06
Lower Limbs Erythema, Week 2 (n=326,326,331,106)2.60 ± 0.042.44 ± 0.052.61 ± 0.052.92 ± 0.07
Lower Limbs Erythema, Week 4 (n=320,323,328,102)2.17 ± 0.051.98 ± 0.052.15 ± 0.052.75 ± 0.07
Lower Limbs Erythema, Week 8 (n=315,319,323,99)1.77 ± 0.061.50 ± 0.051.62 ± 0.052.55 ± 0.08
Lower Limbs Erythema, Week 12 (n=313,311,309,95)1.56 ± 0.061.21 ± 0.061.35 ± 0.052.45 ± 0.09
Lower Limbs Induration Baseline(n=329,329,335,107)2.94 ± 0.042.97 ± 0.043.00 ± 0.042.92 ± 0.07
Lower Limbs Induration, Week 2 (n=326,326,331,106)2.47 ± 0.042.26 ± 0.052.45 ± 0.042.69 ± 0.07
Lower Limbs Induration, Week 4 (n=320,323,328,102)2.03 ± 0.051.72 ± 0.051.92 ± 0.052.54 ± 0.07
Lower Limbs Induration, Week 8 (n=315,319,323,99)1.58 ± 0.061.18 ± 0.051.38 ± 0.052.25 ± 0.08
Lower Limbs Induration, Week 12 (n=313,311,309,95)1.40 ± 0.060.97 ± 0.051.10 ± 0.062.21 ± 0.08
Lower Limbs Scaling, Baseline (n=329,329,335,107)2.91 ± 0.042.95 ± 0.042.98 ± 0.042.89 ± 0.07
Lower Limbs Scaling, Week 2 (n=326,326,331,106)2.36 ± 0.052.25 ± 0.052.31 ± 0.052.62 ± 0.09
Lower Limbs Scaling, Week 4 (n=320,323,328,102)1.98 ± 0.051.69 ± 0.061.81 ± 0.052.44 ± 0.09
Lower Limbs Scaling, Week 8 (n=315,319,323,99)1.60 ± 0.061.21 ± 0.061.32 ± 0.052.11 ± 0.10
Lower Limbs Scaling, Week 12 (n=313,311,309,95)1.39 ± 0.060.96 ± 0.061.08 ± 0.062.09 ± 0.10
SecondaryMean Change From Baseline in PASI Component Scores by Body Region During the 12-Week Double Blind Treatment

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Mean · scores on a scale
Mean Change From Baseline in PASI Component Scores by Body Region During the 12-Week Double Blind Treatment
scores on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Head/Neck Erythema, Week 2 (n=326,326,331,106)-0.46 ± 0.04-0.72 ± 0.05-0.56 ± 0.04-0.15 ± 0.06
Head/Neck Erythema, Week 4 (n=320,323,328,102)-0.80 ± 0.06-1.19 ± 0.06-1.10 ± 0.05-0.32 ± 0.07
Head/Neck Erythema, Week 8 (n=315,319,323,99)-1.09 ± 0.06-1.59 ± 0.06-1.63 ± 0.06-0.54 ± 0.10
Head/Neck Erythema, Week 12 (n=313,311,309,95)-1.25 ± 0.07-1.73 ± 0.07-1.83 ± 0.06-0.64 ± 0.12
Head/Neck Induration, Week 2 (n=326,326,331,106)-0.44 ± 0.04-0.65 ± 0.05-0.49 ± 0.04-0.17 ± 0.06
Head/Neck Induration, Week 4 (n=320,323,328,102)-0.83 ± 0.06-1.15 ± 0.06-0.95 ± 0.05-0.39 ± 0.08
Head/Neck Induration, Week 8 (n=315,319,323,99)-1.08 ± 0.06-1.50 ± 0.06-1.41 ± 0.06-0.58 ± 0.10
Head/Neck Induration, Week 12 (n=313,311,309,95)-1.19 ± 0.06-1.61 ± 0.06-1.57 ± 0.06-0.71 ± 0.11
Head/Neck Scaling, Week 2 (n=326,326,331,106)-0.53 ± 0.04-0.76 ± 0.05-0.67 ± 0.05-0.20 ± 0.07
Head/Neck Scaling, Week 4 (n=320,323,328,102)-0.91 ± 0.06-1.30 ± 0.07-1.13 ± 0.06-0.48 ± 0.08
Head/Neck Scaling, Week 8 (n=315,319,323,99)-1.16 ± 0.07-1.70 ± 0.06-1.62 ± 0.06-0.69 ± 0.10
Head/Neck Scaling, Week 12 (n=313,311,309,95)-1.31 ± 0.07-1.78 ± 0.07-1.81 ± 0.07-0.80 ± 0.11
Upper Limbs Erythema, Week 2 (n=326,326,331,106)-0.52 ± 0.04-0.68 ± 0.04-0.61 ± 0.04-0.18 ± 0.06
Upper Limbs Erythema, Week 4 (n=320,323,328,102)-0.94 ± 0.05-1.13 ± 0.05-1.11 ± 0.04-0.26 ± 0.07
Upper Limbs Erythema, Week 8 (n=315,319,323,99)-1.31 ± 0.06-1.60 ± 0.06-1.62 ± 0.05-0.49 ± 0.08
Upper Limbs Erythema, Week 12 (n=313,311,309,95)-1.42 ± 0.07-1.79 ± 0.06-1.95 ± 0.06-0.58 ± 0.09
Upper Limbs Induration, Week 2 (n=326,326,331,106)-0.52 ± 0.04-0.73 ± 0.04-0.59 ± 0.04-0.25 ± 0.05
Upper Limbs Induration, Week 4 (n=320,323,328,102)-0.94 ± 0.06-1.23 ± 0.05-1.13 ± 0.05-0.39 ± 0.07
Upper Limbs Induration, Week 8 (n=315,319,323,99)-1.26 ± 0.06-1.65 ± 0.06-1.54 ± 0.05-0.67 ± 0.08
Upper Limbs Induration, Week 12 (n=313,311,309,95)-1.39 ± 0.07-1.77 ± 0.06-1.92 ± 0.06-0.68 ± 0.10
Upper Limbs Scaling, Week 2 (n=326,326,331,106)-0.56 ± 0.04-0.72 ± 0.05-0.69 ± 0.04-0.28 ± 0.07
Upper Limbs Scaling, Week 4 (n=320,323,328,102)-0.96 ± 0.05-1.23 ± 0.06-1.19 ± 0.05-0.38 ± 0.08
Upper Limbs Scaling, Week 8 (n=315,319,323,99)-1.28 ± 0.06-1.62 ± 0.06-1.66 ± 0.06-0.64 ± 0.08
Upper Limbs Scaling, Week 12 (n=313,311,309,95)-1.36 ± 0.07-1.73 ± 0.06-1.92 ± 0.06-0.65 ± 0.10
Trunk Erythema, Week 2 (n=326,326,331,106)-0.54 ± 0.04-0.67 ± 0.04-0.63 ± 0.04-0.23 ± 0.06
Trunk Erythema, Week 4 (n=320,323,328,102)-0.91 ± 0.05-1.13 ± 0.05-1.16 ± 0.05-0.35 ± 0.06
Trunk Erythema, Week 8 (n=315,319,323,99)-1.23 ± 0.06-1.66 ± 0.06-1.67 ± 0.06-0.59 ± 0.08
Trunk Erythema, Week 12 (n=313,311,309,95)-1.41 ± 0.07-1.90 ± 0.07-2.03 ± 0.06-0.67 ± 0.10
Trunk Induration, Week 2 (n=326,326,331,106)-0.49 ± 0.04-0.69 ± 0.04-0.61 ± 0.04-0.27 ± 0.06
Trunk Induration, Week 4 (n=320,323,328,102)-0.93 ± 0.06-1.20 ± 0.06-1.17 ± 0.05-0.37 ± 0.07
Trunk Induration, Week 8 (n=315,319,323,99)-1.26 ± 0.06-1.74 ± 0.06-1.68 ± 0.06-0.62 ± 0.10
Trunk Induration, Week 12 (n=313,311,309,95)-1.43 ± 0.07-1.91 ± 0.07-1.99 ± 0.06-0.64 ± 0.11
Trunk Scaling, Week 2 (n=326,326,331,106)-0.52 ± 0.05-0.74 ± 0.05-0.64 ± 0.05-0.25 ± 0.07
Trunk Scaling, Week 4 (n=320,323,328,102)-0.92 ± 0.06-1.27 ± 0.06-1.15 ± 0.05-0.47 ± 0.08
Trunk Scaling, Week 8 (n=315,319,323,99)-1.19 ± 0.06-1.71 ± 0.06-1.67 ± 0.06-0.75 ± 0.09
Trunk Scaling, Week 12 (n=313,311,309,95)-1.38 ± 0.07-1.92 ± 0.06-1.94 ± 0.06-0.71 ± 0.10
Lower Limbs Erythema, Week 2 (n=326,326,331,106)-0.52 ± 0.04-0.69 ± 0.04-0.53 ± 0.04-0.20 ± 0.05
Lower Limbs Erythema, Week 4 (n=320,323,328,102)-0.95 ± 0.05-1.15 ± 0.05-1.00 ± 0.04-0.32 ± 0.06
Lower Limbs Erythema, Week 8 (n=315,319,323,99)-1.34 ± 0.06-1.63 ± 0.05-1.51 ± 0.05-0.55 ± 0.08
Lower Limbs Erythema, Week 12 (n=313,311,309,95)-1.55 ± 0.07-1.92 ± 0.07-1.80 ± 0.06-0.61 ± 0.09
Lower Limbs Induration, Week 2 (n=326,326,331,106)-0.47 ± 0.04-0.71 ± 0.04-0.56 ± 0.04-0.24 ± 0.05
Lower Limbs Induration, Week 4 (n=320,323,328,102)-0.92 ± 0.05-1.25 ± 0.05-1.08 ± 0.05-0.35 ± 0.07
Lower Limbs Induration, Week 8 (n=315,319,323,99)-1.37 ± 0.06-1.80 ± 0.06-1.62 ± 0.06-0.66 ± 0.08
Lower Limbs Induration, Week 12 (n=313,311,309,95)-1.56 ± 0.07-2.01 ± 0.06-1.91 ± 0.06-0.67 ± 0.09
Lower Limbs Scaling, Week 2 (n=326,326,331,106)-0.55 ± 0.04-0.69 ± 0.05-0.67 ± 0.04-0.27 ± 0.06
Lower Limbs Scaling, Week 4 (n=320,323,328,102)-0.94 ± 0.05-1.26 ± 0.06-1.18 ± 0.05-0.43 ± 0.09
Lower Limbs Scaling, Week 8 (n=315,319,323,99)-1.31 ± 0.06-1.74 ± 0.06-1.67 ± 0.06-0.75 ± 0.09
Lower Limbs Scaling, Week 12 (n=313,311,309,95)-1.53 ± 0.07-1.99 ± 0.06-1.92 ± 0.07-0.76 ± 0.10
SecondaryMean Percentage of Total Psoriatic BSA During the 12-Week Double-Blind Treatment

Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The % surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

Time frame:
Baseline and Weeks 2, 4, 8, and 12
Reported as:
Mean · percent psoriatic BSA
Mean Percentage of Total Psoriatic BSA During the 12-Week Double-Blind Treatment
percent psoriatic BSACP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline (n=329,329,335,107)32.15 ± 0.9831.74 ± 0.9530.63 ± 1.0031.88 ± 1.62
Week 2 (n=326,326,331,106)29.53 ± 0.9628.12 ± 0.9428.29 ± 0.9732.03 ± 1.76
Week 4 (n=320,323,328,102)25.98 ± 0.9622.88 ± 0.9324.82 ± 0.9532.47 ± 1.89
Week 8 (n=315,319,323,99)19.74 ± 0.9814.76 ± 0.8915.42 ± 0.8131.00 ± 1.98
Week 12 (n=313,311,309,95)16.04 ± 0.9410.55 ± 0.7710.60 ± 0.7629.77 ± 2.12
SecondaryMean Percent Change From Baseline in Total Psoriatic BSA During the 12-Week Double-Blind Treatment

Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant(fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Mean · percent change from baseline
Mean Percent Change From Baseline in Total Psoriatic BSA During the 12-Week Double-Blind Treatment
percent change from baselineCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 2 (n=326,326,331,106)-7.54 ± 1.23-11.71 ± 1.12-7.54 ± 0.960.23 ± 1.89
Week 4 (n=320,323,328,102)-19.90 ± 1.66-29.17 ± 1.69-19.60 ± 1.461.58 ± 2.84
Week 8 (n=315,319,323,99)-37.81 ± 2.81-55.02 ± 1.93-48.65 ± 1.91-1.33 ± 3.57
Week 12 (n=313,311,309,95)-47.66 ± 3.35-67.51 ± 1.86-64.91 ± 1.91-6.68 ± 4.06
SecondaryPercentage of Participants Who Achieved a 50% Reduction in PASI Relative to Baseline (PASI50) During the 12-Week Double-Blind Treatment

PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.

Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participatns
Percentage of Participants Who Achieved a 50% Reduction in PASI Relative to Baseline (PASI50) During the 12-Week Double-Blind Treatment
percentage of participatnsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 2 (n=326,327,331,106)10.7418.3511.180.94
Week 4 (n=319,323,328,102)33.2350.4648.786.86
Week 8 (n=315,319, 323,99)59.0578.0677.0920.20
Week 12 (n=313,311,309,95)69.0185.5387.0623.16
SecondaryMedian Time to PASI50 Response During the 12-Week Double-Blind Treatment
Time frame:
Baseline up to Week 12
Reported as:
Median · weeks
Median Time to PASI50 Response During the 12-Week Double-Blind Treatment
weeksCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Median Time to PASI50 Response During the 12-Week Double-Blind Treatment8.1 (NA to NA)5.0 (4.1 to 8.0)7.9 (4.4 to 8.0)NA (NA to NA)
SecondaryPercentage of Participants Who Achieved a 90% Reduction in PASI Relative to Baseline (PASI90) During the 12-Week Double-Blind Treatment

PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.

Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a 90% Reduction in PASI Relative to Baseline (PASI90) During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 2 (n=326,327,331,106)0.000.610.300.00
Week 4 (n=319,323,328,102)1.574.641.830.00
Week 8 (n=315,319,323,99)12.0626.0215.790.00
Week 12 (n=313,311,309,95)22.0438.2634.951.05
SecondaryMedian Time to Achieve PASI75 Response During the 12-Week Double-Blind Treatment
Time frame:
Baseline up to Week 12
Reported as:
Median · weeks
Median Time to Achieve PASI75 Response During the 12-Week Double-Blind Treatment
weeksCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Median Time to Achieve PASI75 Response During the 12-Week Double-Blind Treatment12.6 (12.4 to 13.1)8.6 (8.1 to 12.1)12.1 (11.1 to 12.1)NA (NA to NA)
SecondaryPercentage of Participants With a PASI Score Greater Than or Equal to (≥)125% of the Baseline PASI Score During the 12-Week Double-Blind Treatment
Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI Score Greater Than or Equal to (≥)125% of the Baseline PASI Score During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 2 (n=326,327,331,106)0.920.610.304.72
Week 4 (n=319,323,328,102)2.190.930.918.82
Week 8 (n=315,319,323,99)2.540.310.317.07
Week 12 (n=313,311,309,95)2.880.320.977.37
Overall (n=327,329,334,107)4.591.821.8015.89
SecondaryMean Itch Severity Item (ISI) Score During the 12-Week Double-Blind Treatment

ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Mean · score on a scale
Mean Itch Severity Item (ISI) Score During the 12-Week Double-Blind Treatment
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline (n=305,308,305,107)5.19 ± 0.165.26 ± 0.165.23 ± 0.155.15 ± 0.27
Week 2 (n=325,322,330,105)3.47 ± 0.152.87 ± 0.143.90 ± 0.154.90 ± 0.30
Week 4 (n=318,323,328,101)2.92 ± 0.151.86 ± 0.132.97 ± 0.134.65 ± 0.31
Week 8 (n=313,315,320,100)2.11 ± 0.141.22 ± 0.112.06 ± 0.134.74 ± 0.32
Week 12 (n=312,309,311,95)1.98 ± 0.141.25 ± 0.121.72 ± 0.134.75 ± 0.32
SecondaryMean Change From Baseline in ISI Score During the 12-Week Double-Blind Treatment

ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Mean · score on a scale
Mean Change From Baseline in ISI Score During the 12-Week Double-Blind Treatment
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 2-1.73 ± 0.15-2.39 ± 0.14-1.22 ± 0.15-0.26 ± 0.22
Week 4-2.24 ± 0.18-3.43 ± 0.17-2.20 ± 0.15-0.44 ± 0.24
Week 8-3.01 ± 0.18-4.02 ± 0.17-3.13 ± 0.17-0.46 ± 0.26
Week 12-3.18 ± 0.18-3.96 ± 0.18-3.46 ± 0.19-0.43 ± 0.28
SecondaryPercentage of Participants Achieving an ISI Score of 0 During the 12-Week Double-Blind Treatment

ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ISI Score of 0 During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 210.4213.8810.541.02
Week 415.6634.2814.092.13
Week 829.4547.8328.676.38
Week 1231.6451.8540.076.74
SecondaryMean Dermatology Life Quality Index (DLQI) Score During the 12-Week Double-Blind Treatment

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline and Weeks 4 and 12
Reported as:
Mean · score on a scale
Mean Dermatology Life Quality Index (DLQI) Score During the 12-Week Double-Blind Treatment
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline (n=328,326,332,106)12.98 ± 0.3913.32 ± 0.3812.73 ± 0.3812.27 ± 0.69
Week 4 (n=318,323,325,100)7.82 ± 0.365.95 ± 0.326.90 ± 0.3510.51 ± 0.77
Week 12 (n=306,305,307,93)5.61 ± 0.363.47 ± 0.273.84 ± 0.3010.33 ± 0.81
SecondaryMean Change From Baseline in DLQI Score During the 12-Week Double-Blind Treatment

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4 and 12
Reported as:
Mean · score on a scale
Mean Change From Baseline in DLQI Score During the 12-Week Double-Blind Treatment
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 4 (n=317,319,322,99)-5.28 ± 0.35-7.43 ± 0.36-5.80 ± 0.33-1.64 ± 0.55
Week 12 (n=305,301,305,93)-7.33 ± 0.43-9.72 ± 0.40-8.97 ± 0.40-1.85 ± 0.66
SecondaryMean DLQI Subscale Scores During the 12-Week Double-Blind Treatment

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).

Time frame:
Baseline and Weeks 4 and 12
Reported as:
Mean · score on a scale
Mean DLQI Subscale Scores During the 12-Week Double-Blind Treatment
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Symptoms and Feelings,Baseline (n=328,327,332,106)3.44 ± 0.093.49 ± 0.083.47 ± 0.083.46 ± 0.16
Symptoms and Feelings, Week 4 (n=318,323,324,100)2.11 ± 0.081.63 ± 0.071.94 ± 0.072.92 ± 0.15
Symptoms and Feelings, Week 12 (n=306,304,307,93)1.60 ± 0.091.04 ± 0.071.16 ± 0.072.85 ± 0.17
Daily Activities,Baseline (n=327,327,332,106)2.76 ± 0.102.85 ± 0.092.76 ± 0.092.52 ± 0.16
Daily Activities, Week 4 (n=318,322,324,100)1.68 ± 0.081.30 ± 0.081.53 ± 0.082.28 ± 0.18
Daily Activities, Week 12 (n=306,305,306,93)1.19 ± 0.080.70 ± 0.070.79 ± 0.072.17 ± 0.19
Leisure, Baseline (n=326,326,330,106)2.52 ± 0.112.67 ± 0.112.57 ± 0.112.25 ± 0.17
Leisure, Week 4 (n=318,322,325,100)1.50 ± 0.091.14 ± 0.081.33 ± 0.091.84 ± 0.18
Leisure, Week 12 (n=306,305,307,93)1.09 ± 0.090.70 ± 0.070.71 ± 0.071.90 ± 0.19
Work and School,Baseline (n=328,327,331,106)1.12 ± 0.061.08 ± 0.061.06 ± 0.060.97 ± 0.11
Work and School, Week 4 (n=318,323,325,100)0.56 ± 0.050.46 ± 0.050.54 ± 0.050.81 ± 0.11
Work and School, Week 12 (n=306,304,307,92)0.41 ± 0.040.24 ± 0.040.32 ± 0.040.83 ± 0.12
Personal Relationships,Baseline(n=328,326,332,106)1.95 ± 0.111.98 ± 0.101.67 ± 0.101.89 ± 0.18
Personal Relationships, Week 4 (n=318,323,325,100)1.21 ± 0.090.90 ± 0.080.93 ± 0.081.64 ± 0.20
Personal Relationships, Week 12 (n=306,305,307,93)0.85 ± 0.090.48 ± 0.060.52 ± 0.071.65 ± 0.20
Treatment, Baseline(n=328,327,332,106)1.22 ± 0.061.24 ± 0.061.23 ± 0.061.18 ± 0.10
Treatment, Week 4 (n=318,323,325,100)0.76 ± 0.050.52 ± 0.040.65 ± 0.041.02 ± 0.11
Treatment, Week 12 (n=306,305,307,93)0.45 ± 0.040.31 ± 0.030.33 ± 0.040.95 ± 0.11
SecondaryMean Change From Baseline in DLQI Subscale Scores During the 12-Week Double-Blind Treatment

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4 and 12
Reported as:
Mean · scores on a scale
Mean Change From Baseline in DLQI Subscale Scores During the 12-Week Double-Blind Treatment
scores on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Symptoms and Feelings, Week 4 (n=317,320,321,99)-1.34 ± 0.09-1.87 ± 0.08-1.53 ± 0.08-0.53 ± 0.15
Symptoms and Feelings, Week 12 (n=305,301,305,93)-1.81 ± 0.10-2.41 ± 0.10-2.30 ± 0.10-0.62 ± 0.18
Daily Activities, Week 4 (n=316,319,321,99)-1.13 ± 0.09-1.57 ± 0.09-1.21 ± 0.09-0.28 ± 0.15
Daily Activities, Week 12 (n=304,302,304,93)-1.58 ± 0.10-2.14 ± 0.10-1.96 ± 0.10-0.34 ± 0.19
Leisure, Week 4 (n=316,318,320,99)-1.03 ± 0.10-1.54 ± 0.10-1.24 ± 0.10-0.39 ± 0.15
Leisure, Week 12 (n=303,301,303,93)-1.41 ± 0.11-1.95 ± 0.11-1.90 ± 0.11-0.31 ± 0.18
Work and School, Week 4 (n=317,320,321,99)-0.56 ± 0.06-0.63 ± 0.06-0.52 ± 0.06-0.13 ± 0.10
Work and School, Week 12 (n=305,301,304,92)-0.69 ± 0.07-0.86 ± 0.06-0.77 ± 0.07-0.12 ± 0.10
Personal Relationships, Week 4 (n=317,319,322,99)-0.76 ± 0.09-1.09 ± 0.09-0.73 ± 0.08-0.18 ± 0.14
Personal Relationships, Week 12 (n=305,301,305,93)-1.10 ± 0.11-1.46 ± 0.10-1.17 ± 0.09-0.20 ± 0.15
Treatment, Week 4 (n=317,320,322,99)-0.47 ± 0.06-0.72 ± 0.06-0.58 ± 0.06-0.12 ± 0.10
Treatment, Week 12 (n=305,302,305,93)-0.75 ± 0.06-0.91 ± 0.06-0.91 ± 0.06-0.24 ± 0.10
SecondaryPercentage of Participants Achieving DLQI Response ≥5 During the 12-Week Double-Blind Treatment

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Weeks 4 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DLQI Response ≥5 During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 460.9371.3861.3536.59
Week 1271.5485.2881.3435.90
SecondaryPercentage of Participants Achieving DLQI Response ≤1 During the 12-Week Double-Blind Treatment

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Weeks 4 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DLQI Response ≤1 During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 413.0721.7915.517.37
Week 1233.2251.3647.188.89
SecondaryMedian Time to DLQI Response

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. DLQI Response was defined as a 5-point reduction in the total DLQI score.

Time frame:
Weeks 4 and 12

No measurements were reported for this outcome.

SecondaryMean Short Form 36 (SF-36) Mental Component Summary (MCS) and Physical Component Summary (PCS) Scores at Baseline and Week 12

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Higher scores indicate a better health related quality of life.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Mean Short Form 36 (SF-36) Mental Component Summary (MCS) and Physical Component Summary (PCS) Scores at Baseline and Week 12
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline Physical Health Score (n=327,327,327,105)47.4 ± 0.548.3 ± 0.547.5 ± 0.546.8 ± 1.0
Week 12 Physical Health Score (n=303,304,307,95)51.7 ± 0.553.6 ± 0.452.5 ± 0.547.8 ± 1.0
Baseline Mental Health Score (n=327,327,327,105)42.0 ± 0.641.2 ± 0.642.0 ± 0.739.8 ± 1.2
Week 12 Mental Health Score (n=303,304,307,95)47.0 ± 0.649.3 ± 0.547.8 ± 0.641.7 ± 1.3
SecondaryMean SF-36 Domain Scores at Baseline and Week 12

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Mean SF-36 Domain Scores at Baseline and Week 12
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline Physical Functioning (n=328,328,330,106)48.3 ± 0.549.0 ± 0.548.6 ± 0.546.7 ± 1.1
Week 12 Physical Functioning (n=306,305,308,95)51.9 ± 0.553.1 ± 0.452.2 ± 0.448.1 ± 1.1
Baseline Role Physical (n=328,328,330,106)45.4 ± 0.645.9 ± 0.645.5 ± 0.644.4 ± 1.1
Week 12 Role Physical (n=307,305,308,95)50.5 ± 0.552.5 ± 0.451.2 ± 0.546.1 ± 1.1
Baseline Bodily Pain (n=328,329,331,107)44.5 ± 0.745.6 ± 0.744.0 ± 0.743.6 ± 1.2
Week 12 Bodily Pain (n=306,305,307,95)51.7 ± 0.654.6 ± 0.552.4 ± 0.645.7 ± 1.3
Baseline General Health (n=328,328,330,106)43.4 ± 0.542.8 ± 0.543.5 ± 0.642.4 ± 1.0
Week 12 General Health (n=305,304,308,95)46.2 ± 0.548.5 ± 0.547.9 ± 0.542.6 ± 1.0
Baseline Vitality (n=328,329,331,107)47.9 ± 0.548.5 ± 0.648.3 ± 0.546.5 ± 1.0
Week 12 Vitality (n=306,305,307,95)52.4 ± 0.554.4 ± 0.552.9 ± 0.547.9 ± 1.1
Baseline Social Functioning (n=328,329,331,107)41.6 ± 0.641.1 ± 0.642.3 ± 0.740.7 ± 1.2
Week 12 Social Functioning (n=306,305,307,95)47.8 ± 0.650.6 ± 0.549.3 ± 0.542.0 ± 1.2
Baseline Role-Emotional (n=328,329,331,107)43.2 ± 0.742.4 ± 0.743.1 ± 0.740.4 ± 1.3
Week 12 Role-Emotional (n=306,305,307,95)48.6 ± 0.550.2 ± 0.548.6 ± 0.643.3 ± 1.4
Baseline Mental Health (n=328,329,331,107)42.0 ± 0.641.5 ± 0.641.7 ± 0.739.5 ± 1.2
Week 12 Mental Health (n=306,305,307,95)46.6 ± 0.648.9 ± 0.547.5 ± 0.641.4 ± 1.2
Baseline Health Transition (n=328,329,331,107)3.2 ± 0.03.2 ± 0.03.1 ± 0.03.2 ± 0.1
Week 12 Health Transition (n=306,305,307,95)2.6 ± 0.02.6 ± 0.02.5 ± 0.03.0 ± 0.1
SecondaryMean Change From Baseline in SF-36 MCS and PCS Scores

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Higher scores indicate a better health related quality of life.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Mean Change From Baseline in SF-36 MCS and PCS Scores
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Physical Health Score4.1 ± 0.45.0 ± 0.55.2 ± 0.50.8 ± 0.7
Mental Health Score5.0 ± 0.67.6 ± 0.65.8 ± 0.61.5 ± 1.1
SecondaryMean Change From Baseline in SF-36 Domain Scores

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Mean Change From Baseline in SF-36 Domain Scores
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Physical Functioning3.5 ± 0.43.7 ± 0.43.7 ± 0.51.1 ± 0.8
Role Physical5.1 ± 0.56.3 ± 0.66.1 ± 0.51.3 ± 0.9
Bodily Pain7.0 ± 0.78.5 ± 0.68.6 ± 0.71.6 ± 1.0
General Health2.5 ± 0.55.5 ± 0.54.4 ± 0.50.2 ± 0.8
Vitality4.2 ± 0.55.4 ± 0.54.6 ± 0.51.3 ± 0.9
Social Functioning6.0 ± 0.79.2 ± 0.67.3 ± 0.60.7 ± 1.1
Role - Emotional5.4 ± 0.67.2 ± 0.65.8 ± 0.72.3 ± 1.2
Mental Health4.5 ± 0.67.0 ± 0.65.9 ± 0.61.4 ± 1.1
Health Transition-0.5 ± 0.1-0.6 ± 0.1-0.6 ± 0.1-0.2 ± 0.1
SecondaryPercentage of Participants in Each Patient Global Assessment of Psoriasis (PtGA) Category During the 12-Week Double-Blind Treatment

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).

Time frame:
Baseline and Weeks 2, 4, and 8
Reported as:
Number · percentage of participants
Percentage of Participants in Each Patient Global Assessment of Psoriasis (PtGA) Category During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Clear, Baseline (n=328,328,330,107)0.00.00.00.0
Almost Clear, Baseline (n=328,328,330,107)0.00.30.30.0
Mild, Baseline (n=328,328,330,107)3.41.54.23.7
Moderate, Baseline (n=328,328,330,107)32.330.228.523.4
Severe, Baseline (n=328,328,330,107)64.368.067.072.9
Clear, Week 2 (n=324,322,331,106)0.30.00.30.0
Almost Clear, Week 2 (n=324,322,331,106)1.24.31.20.9
Mild, Week 2 (n=324,322,331,106)13.314.911.82.8
Moderate, Week 2 (n=324,322,331,106)49.454.352.038.7
Severe, Week 2 (n=324,322,331,106)35.826.434.757.5
Clear, Week 4 (n=319,323,324,100)0.30.60.30.0
Almost Clear, Week 4 (n=319,323,324,100)6.917.09.30.0
Mild, Week 4 (n=319,323,324,100)21.630.726.55.0
Moderate, Week 4 (n=319,323,324,100)46.736.843.535.0
Severe, Week 4 (n=319,323,324,100)24.514.920.460.0
Clear, Week 8 (n=313,317,315,97)2.94.73.50.0
Almost Clear, Week 8 (n=313,317,315,97)16.938.229.84.1
Mild, Week 8 (n=313,317,315,97)33.527.133.07.2
Moderate, Week 8 (n=313,317,315,97)31.322.124.838.1
Severe, Week 8 (n=313,317,315,97)15.37.98.950.5
SecondaryPercentage of Participants With a PtGA Response During the 12-Week Double-Blind Treatment

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe). Response defined as score of 0 or 1.

Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With a PtGA Response During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Week 2 (n=324,322,331,106)1.544.351.510.94
Week 4 (n=319,323,324,100)7.2117.659.570.00
Week 8 (n=313,317,315,97)19.8142.9033.334.12
Week 12 (n=306,304,309,95)32.6856.2553.071.05
SecondaryPercentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Category During the 12-Week Double-Blind Treatment

The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study medication.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Category During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Very satisfied44.068.562.415.8
Somewhat satisfied27.017.423.515.8
Slightly satisfied11.75.27.211.6
Neither satisfied nor dissatisfied4.62.32.011.6
Slightly dissatisfied2.61.62.04.2
Somewhat dissatisfied4.63.02.012.6
Very dissatisfied5.52.01.028.4
SecondaryPercentage of Participants Achieving PSSM Response of 'Very Satisfied' or 'Somewhat Satisfied' at Week 12

The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study medication.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PSSM Response of 'Very Satisfied' or 'Somewhat Satisfied' at Week 12
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Percentage of Participants Achieving PSSM Response of 'Very Satisfied' or 'Somewhat Satisfied' at Week 1271.0185.9085.9531.58
SecondaryMean European Quality of Life 5 Dimension (EQ-5D) Health State Utility Score During the 12-Week Double-Blind Treatment

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Mean European Quality of Life 5 Dimension (EQ-5D) Health State Utility Score During the 12-Week Double-Blind Treatment
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline0.7 ± 0.00.7 ± 0.00.7 ± 0.00.6 ± 0.0
Week 120.8 ± 0.00.9 ± 0.00.9 ± 0.00.7 ± 0.0
SecondaryLeast Squares (LS) Mean Change From Baseline in EQ-5D Health State Utility Score During the 12-Week Double-Blind Treatment

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Week 12
Reported as:
Least squares mean · scores on a scale
Least Squares (LS) Mean Change From Baseline in EQ-5D Health State Utility Score During the 12-Week Double-Blind Treatment
scores on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Least Squares (LS) Mean Change From Baseline in EQ-5D Health State Utility Score During the 12-Week Double-Blind Treatment0.14 ± 0.0110.21 ± 0.0110.19 ± 0.0110.03 ± 0.021
SecondaryMean EQ-5D Visual Analog Score (VAS) During the 12-Week Double-Blind Treatment

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline and Week 12
Reported as:
Mean · mm
Mean EQ-5D Visual Analog Score (VAS) During the 12-Week Double-Blind Treatment
mmCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline (n=315,318,312,100)63.3 ± 1.363.3 ± 1.364.2 ± 1.360.5 ± 2.7
Week 12 (n=298,294,297,91)75.3 ± 1.181.1 ± 1.080.0 ± 1.065.1 ± 2.6
SecondaryMean Change From Baseline in EQ-5D VAS at Week 12

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

Time frame:
Week 12
Reported as:
Mean · mm
Mean Change From Baseline in EQ-5D VAS at Week 12
mmCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Mean Change From Baseline in EQ-5D VAS at Week 1211.6 ± 1.416.6 ± 1.515.7 ± 1.43.0 ± 2.4
SecondaryDimension Health State EQ-5D Score During the 12-Week Double-Blind Treatment

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").

Time frame:
Baseline and Week 12
Reported as:
Mean · Units on a scale
Dimension Health State EQ-5D Score During the 12-Week Double-Blind Treatment
Units on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Mobility, Baseline (n=326,327,330,104)1.3 ± 0.01.3 ± 0.01.3 ± 0.01.3 ± 0.0
Mobility, Week 12 (n=306,304,307,95)1.2 ± 0.01.1 ± 0.01.2 ± 0.01.3 ± 0.1
Self Care, Baseline (n=327,327,330,104)1.2 ± 0.01.1 ± 0.01.1 ± 0.01.2 ± 0.0
Self Care, Week 12 (n=306,304,307,95)1.1 ± 0.01.0 ± 0.01.1 ± 0.01.2 ± 0.0
Usual Activities, Baseline (n=327,327,330,104)1.4 ± 0.01.4 ± 0.01.4 ± 0.01.5 ± 0.1
Usual Activities, Week 12 (n=307,304,307,95)1.2 ± 0.01.1 ± 0.01.2 ± 0.01.3 ± 0.1
Pain/Discomfort, Baseline (n=327,328,330,104)1.8 ± 0.01.8 ± 0.01.9 ± 0.01.8 ± 0.1
Pain/Discomfort, Week 12 (n=307,304,307,95)1.5 ± 0.01.3 ± 0.01.4 ± 0.01.7 ± 0.1
Anxiety/Depression, Baseline (n=326,327,330,104)1.6 ± 0.01.7 ± 0.01.6 ± 0.01.7 ± 0.1
Anxiety/Depression, Week 12 (n=305,304,307,95)1.4 ± 0.01.3 ± 0.01.3 ± 0.01.5 ± 0.1
SecondaryMean Change From Baseline in EQ-5D Dimension Health State Score at Week 12

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").

Time frame:
Week 12
Reported as:
Mean · scores on a scale
Mean Change From Baseline in EQ-5D Dimension Health State Score at Week 12
scores on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Mobility-0.1 ± 0.0-0.1 ± 0.0-0.1 ± 0.0-0.0 ± 0.0
Self-Care-0.1 ± 0.0-0.1 ± 0.0-0.1 ± 0.0-0.1 ± 0.0
Usual Activities-0.3 ± 0.0-0.3 ± 0.0-0.2 ± 0.0-0.1 ± 0.1
Pain/Discomfort-0.4 ± 0.0-0.5 ± 0.0-0.5 ± 0.0-0.1 ± 0.1
Anxiety/Depression-0.2 ± 0.0-0.4 ± 0.0-0.3 ± 0.0-0.1 ± 0.1
SecondaryPercentage of Participants Interacting With Healthcare Professionals During the 12-Week Double-Blind Treatment

The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners \[GPs\], primary care physicians \[PCPs\], or family medicine physicians \[FMP\], emergency room visits, and hospitalizations), and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work.

Time frame:
Baseline (BL) and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Interacting With Healthcare Professionals During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline, GP/PCP/FMP (n=230,220,224,77)0.80.91.32.5
Baseline, Dermatologist (n=230,220,224,77)6.94.57.510.3
Baseline, Rheumatologist (n=230,220,224,77)0.00.00.00.0
Baseline, Cardiologist (n=230,220,224,77)0.40.40.42.5
Baseline, Gastroenterologist (n=230,220,224,77)0.40.00.00.0
Baseline, Psychiatrist (n=230,220,224,77)0.00.40.01.2
Baseline, Surgeon (n=230,220,224,77)0.40.00.00.0
Baseline, Nurse (n=230,220,224,77)1.31.30.82.5
Baseline, Other (n=230,220,224,77)2.10.90.01.2
Week 12, GP/PCP/FMP (n=255,251,261,79)10.16.78.48.8
Week 12, Dermatologist (n=255,251,261,79)8.24.35.77.5
Week 12, Rheumatologist (n=255,251,261,79)0.71.10.70.0
Week 12, Cardiologist (n=255,251,261,79)1.51.92.61.2
Week 12, Gastroenterologist (n=255,251,261,79)1.11.51.50.0
Week 12, Psychiatrist (n=255,251,261,79)0.00.71.50.0
Week 12, Surgeon (n=255,251,261,79)0.30.30.00.0
Week 12, Nurse (n=255,251,261,79)1.11.92.60.0
Week 12, Other (n=255,251,261,79)8.65.16.82.5
SecondaryPercentage of Participants Reporting Healthcare Resource Use Events During the 12-Week Double-Blind Treatment
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Healthcare Resource Use Events During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Percentage of Participants Reporting Healthcare Resource Use Events During the 12-Week Double-Blind Treatment10.439.7810.088.45
SecondaryPercentage of Participants Employed or Not Employed and the Impact of Psoriasis on Work

Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The questionnaire assesses employment status of participant (employed: yes or no) and if currently employed it asks the participant if they were absent or on sick leave from work due to psoriasis; if unemployed it asks the participant if the unemployment is due to psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Employed or Not Employed and the Impact of Psoriasis on Work
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline, employed67.871.272.371.4
Baseline, absent/sick leave due to psoriasis18.321.022.323.4
Baseline, not employed32.228.827.728.6
Baseline, unemployed due to psoriasis9.67.36.32.6
Week 12, employed69.273.869.168.1
Week 12, absent/sick leave due to psoriasis13.214.715.717.4
Week 12, not employed30.826.230.931.9
Week 12, unemployed due to psoriasis4.04.94.74.3
SecondaryPercentage of Participants Reporting Work-Impacted Events During the 12-Week Double-Blind Treatment

Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Work-Impacted Events During the 12-Week Double-Blind Treatment
percentage of participantsCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Percentage of Participants Reporting Work-Impacted Events During the 12-Week Double-Blind Treatment37.9730.4934.1556.25
SecondaryMean Psoriasis Quality of Life 12 (PQOL-12) Score During the 12-Week Double-Blind Treatment

The PQOL-12 is a 12-item questionnaire; 8 of the items on the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Mean Psoriasis Quality of Life 12 (PQOL-12) Score During the 12-Week Double-Blind Treatment
score on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Baseline (n=323,326,331,105)75.4 ± 1.577.0 ± 1.575.7 ± 1.574.9 ± 2.9
Week 12 (n=303,303,306,92)40.0 ± 1.829.2 ± 1.631.0 ± 1.765.5 ± 3.5
SecondaryMean Change From Baseline in PQOL-12 Score During the 12-Week Double-Blind Treatment

The PQOL-12 is a 12-item questionnaire; 8 of the items on the PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.

Time frame:
Week 12
Reported as:
Mean · scores on a scale
Mean Change From Baseline in PQOL-12 Score During the 12-Week Double-Blind Treatment
scores on a scaleCP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIW
Mean Change From Baseline in PQOL-12 Score During the 12-Week Double-Blind Treatment-35.2 ± 1.9-47.9 ± 1.8-44.3 ± 1.8-9.6 ± 2.6

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CP-690,550 5 mg BID—7/329 (2.1%)103/329 (31.3%)
CP-690,550 10 mg BID—5/330 (1.5%)121/330 (36.7%)
Etanercept 50 mg BIW—7/335 (2.1%)109/335 (32.5%)
Placebo—2/107 (1.9%)34/107 (31.8%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventCP-690,550 5 mg BIDCP-690,550 10 mg BIDEtanercept 50 mg BIWPlacebo
PsoriasisSkin and subcutaneous tissue disorders0/3292/3301/3352/107
Oedema peripheralGeneral disorders0/3290/3300/3351/107
Myocardial infarctionCardiac disorders1/3290/3300/3350/107
DiverticulitisInfections and infestations1/3290/3300/3350/107
Extradural abscessInfections and infestations1/3290/3300/3350/107
Foot fractureInjury, poisoning and procedural complications1/3290/3300/3350/107
Lower limb fractureInjury, poisoning and procedural complications1/3290/3300/3350/107
Rib fractureInjury, poisoning and procedural complications1/3290/3300/3350/107
Thoracic vertebral fractureInjury, poisoning and procedural complications1/3290/3300/3350/107
DepressionPsychiatric disorders1/3290/3300/3350/107
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCP-690,550 5 mg BIDCP-690,550 10 mg BIDEtanercept 50 mg BIWPlacebo
NasopharyngitisInfections and infestations21/32930/33025/33510/107
HeadacheNervous system disorders21/32924/33013/3354/107
Injection site erythemaGeneral disorders0/3291/33018/3350/107
Blood creatine phosphokinase increasedInvestigations15/32916/33010/3350/107
DyslipidaemiaMetabolism and nutrition disorders10/32915/3303/3351/107
HypercholesterolaemiaMetabolism and nutrition disorders11/32914/3305/3352/107
PsoriasisSkin and subcutaneous tissue disorders3/3291/3302/3354/107
Injection site reactionGeneral disorders0/3290/33012/3350/107
Blood cholesterol increasedInvestigations9/32911/3307/3350/107
ArthralgiaMusculoskeletal and connective tissue disorders8/32910/3304/3351/107

Baseline characteristics

Full Analysis Set (FAS): included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550, etanercept, or placebo).

Age, Continuous
Age, Continuous(years)CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIWTotal
Mean44.4 ± 12.143.6 ± 12.643.3 ± 12.246.1 ± 13.444.0 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)CP-690,550 10 mg BID + Placebo BIWPlacebo BID + Etanercept 50 mg BIWPlacebo BID + Placebo BIWTotal
Female939210236323
Male23623823371778
08

Study locations

122 sites
  • Centro de Investigaciones Dermatologicas
    Ciudad Autonoma de Buenos Aires, C1114aap, Argentina
  • Centro de Investigaciones Dermatologicas
    Ciudad Autonoma de Buenos Aires, C1114AAP, Argentina
  • IMAI (Instituto Medico de Asistencia e Investigaciones)
    Ciudad Autonoma de Buenos Aires, C1425AWC, Argentina
  • LKH Feldkirch Abteilung fuer Dermatologie und Venerologie
    Feldkirch, A-6807, Austria
  • LKH Innsbruck Universitaetsklinik fuer Dermatologie und Venerologie
    Innsbruck, A-6020, Austria
  • LKH Salzburg, Landesklinik fuer Dermatologie
    Salzburg, 5020, Austria
  • Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhuegel
    Wien, 1130, Austria
  • Cliniques universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Department for skin and venerial diseases, Clinical Center University of Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • Universitetska Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Dr Georgi Stranski- Pleven
    Pleven, 5800, Bulgaria
  • Tsentar za kozhno-venericheski zaboliavania" EOOD
    Sofia, 1404, Bulgaria
  • Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Tokuda Bolnitsa Sofia- Sofia
    Sofia, 1407, Bulgaria
  • Universitetska mnogoprofilna bolnitsa za aktivno lechenie- Alexandrovska- Sofia
    Sofia, 1431, Bulgaria
  • MBAL na Voennomeditsinska akademia- Sofia
    Sofia, 1606, Bulgaria
  • Clinica Davila
    Santiago, Rm 8431657, RM 8420383, Chile
  • Centro de Especialidades Dermatologicas
    Vina del Mar, V Region 00000, Chile
  • Clinica Dermovein S.A.
    Santiago, 7640881, Chile
  • Hospital Clinico Universidad de Chile, Departamento Dermatologia
    Santiago, 8380456, Chile
  • Reumalab S.A.S.
    Medellin, Antioquia 0, Colombia
  • Centro Integral de Reumatología del Caribe Circaribe S.A
    Barranquilla, Atlantico 0000, Colombia
  • Centro de Investigacion Clinica de la Universidad del Rosario
    Bogota, Cundinamarca 0000, Colombia
  • Riesgo de Fractura S.A.
    Bogota, Cundinamarca 0000, Colombia
  • Medicity S.A.S
    Bucaramanga, Santander 0000, Colombia
  • Department of Dermatovenerology, University Hospital Center Osijek
    Osijek, 31000, Croatia
  • Dermatovenerological Clinic, University hospital center "Sestre milosrdnice"
    Zagreb, 10 000, Croatia
  • Department of dermatovenerology, University Hospital Center Zagreb
    Zagreb, 10000, Croatia
  • Nemocnice Ceske Budejovice, a.s.
    Ceske Budejovice, 37001, Czechia
  • FN Kradec Kralove
    Hradec Kralove, 50005, Czechia
  • Fakultni nemocnice Plzen
    Plzen - Bory, 30599, Czechia
  • Kozni ordinace
    Praha 1, 11000, Czechia
  • Kralska zdravotni a.s., Masarykovy nemocnice o.z.
    Usti nad Labem, 40113, Czechia
  • Kralska zdravotni
    Usti nad Labem, 40113, Czechia
  • Department of Dermatology, Aarhus University Hospital
    Aarhus C, 8000, Denmark
  • Bispebjerg Hospital, University of Copenhagen
    Copenhagen NV, 2400, Denmark
  • Hudklinikken Herning
    Herning, 7400, Denmark
  • CHG Le Mans
    Le Mans, Cedex 09 72037, France
  • CHU de Besancon - Hopital Saint Jacques
    Besancon, 25030, France
  • Hopital Ambroise Pare, Service de Dermatologie
    Boulogne, 92104, France
  • Chu Morvan
    BREST Cédex, 29609, France
  • Hopital Dupuytren
    Limoges, 87042, France
  • Hopital Fournier
    NANCY Cédex, 54035, France
  • CHU de Nantes - Hotel Dieu
    Nantes Cedex 1, 44035, France
  • CHU de NICE - Hôpital de l'Archet II
    Nice, 06200, France
  • Hopital Saint-Louis
    Paris, 75010, France
  • Hôpital Bichat
    Paris, 75018, France
  • Centre Hospitalier Lyon Sud
    Pierre-Benite, 69310, France
  • C.H.U. de Poitiers
    Poitiers, 86000, France
  • Hopital Robert Debre
    Reims, 51100, France
  • Hopital Nord
    Saint Priest En Jarez, 42270, France
  • Hôpital Larrey
    Toulouse cedex 9, 31059, France
  • Hôpital de Brabois / Bâtiment Philippe Canton
    Vandoeuvre-les-Nancy, 54511, France
  • Charite - Universitaetsmedizin Berlin
    Berlin, 10117, Germany
  • Hautarztpraxis
    Berlin, 13507, Germany
  • Dres.Kirsten Prepeneit und Volker Streit
    Buchholz, 21244, Germany
  • Universitaetsklinik Carl Gustav Carus
    Dresden, 01307, Germany
  • Hautzentrum Duelmen
    Duelmen, 48249, Germany
  • Universitaetsklinikum Erlangen Hautklinik im Internistischen Zentrum
    Erlangen, 91054, Germany
  • Klinikum der Johann Wolfgang Goethe Universitaet
    Frankfurt/Main, 60590, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Hautklinik der Ruprecht-Karls-Universitaet Heidelberg
    Heidelberg, 69115, Germany
  • Universitaets- Hautklinik Koeln
    Koeln, 50924, Germany
  • Hautarztpraxis Dres. Scholz, Sebastian, Schilling
    Mahlow, 15831, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KoeR
    Mainz, 55131, Germany
  • Technische Universitaet Muenchen
    Muenchen, 80802, Germany
  • Dres. med. Bredlich/PD Rosenbach/Thiele
    Osnabrueck, 49078, Germany
  • Eberhard-Karls-Universitaet Tuebingen
    Tuebingen, 72076, Germany
  • Hautarztpraxis
    Witten, 58453, Germany
  • The University of Hong Kong (HKU)-Queen Mary Hospital (QMH)
    Hong Kong, 0, Hong Kong
  • Synexus Magyarorszag Kft.
    Budapest, 1036, Hungary
  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum/Bor- es Nemikortani Klinika
    Debrecen, 4032, Hungary
  • Miskolci Semmelweis Ignac Korhaz-Rendelointezet/Borgyogyaszat
    Miskolc, 3529, Hungary
  • SZTE Szentgyorgyi Albert Klinikai Kozpont/Borgyogyaszati es Allergologiai Klinika
    Szeged, 6720, Hungary
  • ALLERGO-DERM BAKOS Kft.
    Szolnok, 5000, Hungary
  • Dermatology Department
    Afula, 18101, Israel
  • Samsung Medical Center / Department of Dermatology
    Gangnam-Gu, Seoul 135-710, Korea, Republic of
  • Severance Hospital, Yonsei University College of Medicine/Department of Dermatology
    Seoul, 120-752, Korea, Republic of
  • Academic Medical Centre (AMC)
    Amsterdam, Noord Holland 1105 AZ, Netherlands
  • PT & R
    Beek, 6191 JW, Netherlands
  • Amphia Hospital Location Molengracht / Department Dermatology
    Breda, 4800 RK, Netherlands
  • Erasmus MC
    Rotterdam, 3015 CA, Netherlands
  • NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik
    Bialystok, 05-354, Poland
  • Klinika Dermatologii, Wenerologii i Alergologii, Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Krakowskie Centrum Medyczne NZOZ
    Krakow, 31-501, Poland
  • Novum Instytut Dermatologii Leczniczej i Estetycznej
    Opole, 45-080, Poland
  • Solumed S.C.
    Poznan, 60-539, Poland
  • Korolev Dermatovenerologic Dispensary
    Korolev, Moscow Region 141070, Russian Federation
  • State Research Center of Dermatovenerology, Department of clinical dermatology
    Moscow, 107076, Russian Federation
  • State Research Center of Dermatovenerology, Department of dermatology
    Moscow, 107076, Russian Federation
  • Dermatovenerologic dispensary #7
    Moscow, 121614, Russian Federation
  • Rostov-on-Don regional dermatovenerologic dispensary
    Rostov-on-Don, 344007, Russian Federation
  • Ryazan regional clinical dermatovenerologic dispensary
    Ryazan, 390046, Russian Federation
  • Dermatovenerologic dispensary #10 of Vyborg region
    Saint-Petersburg, 194021, Russian Federation
  • Military medical academy S.M. Kirov
    Saint-Petersburg, 194044, Russian Federation
  • North-Western State Medical University I.I. Mechnikov, Dermatovenerology Department
    Saint-Petersburg, 195067, Russian Federation
  • Clinic of dermatovenerologic diseases
    Saratov, 410028, Russian Federation
  • Smolensk State Medical Academy
    Smolensk, 214019, Russian Federation
  • Clinical hospital of emergency care N.V. Soloviev
    Yaroslavl, 150003, Russian Federation
  • National Skin Centre
    Singapore, 308205, Singapore
  • Changi General Hospital
    Singapore, 529889, Singapore

Showing the first 100 of 122 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, Mamolo C. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1753-1759. doi: 10.1111/jdv.13702. Epub 2016 Jun 7. PubMed 27271195 ↗
  • Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R; OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015 Aug 8;386(9993):552-61. doi: 10.1016/S0140-6736(14)62113-9. Epub 2015 Jun 4. PubMed 26051365 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2010
First posted
Nov 16, 2010
Start
Nov 2010
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
May 7, 2014
Last update
Dec 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01241591
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 16, 2010
Start date
Nov 2010
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
May 7, 2014
Last update
Dec 26, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion